Development of new immunologic approaches to cancer therapy.
New approaches to the immunotherapy of cancer have been developed based on the adoptive transfer of activated lymphoid cells in conjunction with interleukin-2. This approach is successful in mediating the regression of established pulmonary and hepatic metastases in experimental animal models. The results of preliminary clinical trials in patients with advanced cancer have shown that this treatment approach is capable of mediating regression of cancer in humans as well.
Rosenberg
S A
SA
National Cancer Institute and Clinical Center, Bethesda, Md.
D000818:Animals; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000639:trends*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000637:transplantation; D017710:Lymphocyte Transfusion; D008222:Lymphokines / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy*
D007376:Interleukin-2; D008222:Lymphokines